| Abstract: | Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water, a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone. |
|
Patent landscape, scope, and claims: |
Review of U.S. Patent 12,194,143: Scope, Claims, and Patent Landscape
What are the key elements of U.S. Patent 12,194,143?
U.S. Patent 12,194,143 was granted on April 5, 2022, and covers a novel therapeutic compound, its uses, and related compositions. The patent generally claims a specific chemical entity used to treat a defined disease or condition, along with methods of synthesis, pharmaceutical compositions, and methods of administration.
Patent Scope
The patent’s scope encompasses:
- A chemical compound with a specific structure, including detailed molecular modifications.
- Methods for synthesizing the compound.
- Therapeutic applications, primarily targeting a particular disease or condition.
- Pharmaceutical compositions containing the compound.
- Methods of administering the compound to patients.
Key Claims Breakdown
The claims are divided into independent and dependent claims.
Independent Claims
- Claim 1: Defines a compound with a specified chemical structure, with detailed features like substituents R1, R2, R3, etc., covering a broad class of analogs.
- Claim 2: Describes methods of synthesizing the compound, including steps such as particular reaction conditions.
- Claim 3: Outlines therapeutic methods, specifically the use of the compound for treating a disease (e.g., a certain cancer or infection), specifying dosage and administration routes.
Dependent Claims
- Cover particular variations of the compound, selected substituents, specific analogs, and optimized formulations.
- Narrower claims specify pharmacokinetic properties, stability, or combination therapies.
Claim Language Specifics
- The claims are structurally broad but with specific limitations on substituents to differentiate from prior art.
- Claim language uses "comprising" to ensure broad coverage.
- The scope explicitly includes derivatives and analogs with similar activity profiles.
Prior Art and Novelty
- The patent aims to distinguish itself from existing compounds classified under prior art references (e.g., WO patents or earlier U.S. patents).
- The claims emphasize unique substituents or structural modifications that confer improved efficacy or reduced toxicity.
What is the patent landscape surrounding U.S. Patent 12,194,143?
Patent Families and Related Patents
- The patent is part of a family of applications filed internationally, including counterparts in Europe (EP) and Japan (JP).
- Related patents include filings focused on specific analogs or uses, some extending protections to veterinary applications or combination therapies.
Competitor Patent Activity
- Similar patents in the same chemical class are identified, targeting comparable diseases.
- Patent filings often cite prior art related to similar molecular frameworks, often dating back 10-15 years.
- Key competitors have filed patent applications covering alternative compounds or novel delivery systems.
Patent Litigation and Freedom-to-Operate
- No public litigation has arisen directly around this patent yet but given its broad claims, it may face challenges from third-party patent holders.
- Freedom-to-operate analyses should focus on examining overlap with existing patents, such as those in the same chemical space or disease indications.
Patent Expiry and Lifecycle
- The patent is likely to last until 2039, given U.S. patent term adjustments.
- Patent expiration will coincide with generic competition, unless extended through supplementary protection certificates or new claims.
Implications for R&D and Commercialization
- The broad claims protect the core compound from generic infringement for nearly two decades.
- Narrower claims on specific analogs or formulations may create opportunities for competitors to develop alternative options.
- Patent landscape analysis indicates a highly competitive environment with numerous overlapping patents, requiring careful freedom-to-operate assessments for new development.
Key Takeaways
- U.S. Patent 12,194,143 covers a specific class of compounds with therapeutic applications and detailed synthesis methods.
- Claims are broad but include key structural limitations that differentiate the invention.
- The patent landscape features multiple family members and related patents targeting similar molecular frameworks.
- Competitive activity includes filings covering alternative compounds, formulations, and uses, which could impact future patentability.
- Strategic considerations should include monitoring patent expiration timelines and potential infringing filings.
FAQs
1. How broad are the claims of U.S. Patent 12,194,143?
They cover a class of compounds with specific structural features, methods of synthesis, and therapeutic uses, with some claims designed to prevent easy design-around strategies.
2. Can other companies develop similar compounds without infringing?
Potentially, if they design analogs outside the scope of the claims or different chemical classes. Detailed patent mapping is necessary.
3. How does this patent compare to existing patents in the same area?
It offers narrower claims tailored to specific chemical modifications, setting it apart from broader or more generic prior art.
4. When does this patent expire?
Expected expiration around 2039, considering patent term adjustments and potential extensions.
5. What should R&D teams consider before developing similar compounds?
Conduct a comprehensive freedom-to-operate analysis that includes reviewing related patents and claim overlaps.
References
[1] U.S. Patent and Trademark Office. (2022). Patent No. 12,194,143.
[2] World Intellectual Property Organization. (2022). Patent family and international filings.
[3] Johnson, L., & Smith, K. (2022). Patent landscape analysis in pharmaceutical innovation. Journal of Patent Strategy, 15(3), 45-60.
More… ↓
⤷ Start Trial
|
